Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

(Bloomberg) -- Novo Nordisk A/S can advance with its acquisition ... The three factories, located in Anagni, Italy, Brussels and Bloomington, Indiana, focus on the stages of drug production ...

The three sites in Anagni, Italy, Brussels in Belgium, and Bloomington, Indiana, in the US will change hands “as soon as possible after the merger,” said Novo Nordisk, which has pledged to ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

The letter indicates that Novo Nordisk already has 55% of the market ... sites covered by the deal is located in the US – at Bloomington, Indiana – while the other two are at Anagni in Italy ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

Novo Nordisk (NVO) ended the recent trading session at $67.10, demonstrating a -1.67% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily ...

Novo Nordisk (NVO) closed the most recent trading day at $69.30, moving -1.23% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.97%.